A decades-old glau­co­ma drug tossed aside by Pfiz­er gets a new life at a small biotech

Months ago, Pfiz­er made a grim an­nounce­ment that it would stop man­u­fac­tur­ing phos­pho­line io­dide, its decades-old “mir­a­cle drug” for a rare form of glau­co­ma. The phar­ma said its in­ven­to­ry would run dry by May 2021, leav­ing some pa­tients with few op­tions short of surgery.

But af­ter snag­ging the rights and the rest of Pfiz­er’s sup­ply, a small New York biotech is look­ing to give phos­pho­line io­dide new life.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER